You may be asking what PT-141 is after seeing the name online. Maybe an ad tied it to desire, or a forum called it a peptide. The claims can be confusing.
Low sexual desire is common, and it can weigh on you. It is normal to want real answers, not hype. You deserve facts you can trust.
This page explains PT-141 in everyday words. You will learn what it is, how it works, and who it is approved to help. Every fact here comes from the FDA label and trial results.
KEY TAKEAWAYS
- PT-141 is the research name for bremelanotide, the peptide in the medicine Vyleesi®.
- Vyleesi® is FDA-approved for premenopausal women with acquired, generalized HSDD, used as needed.
- PT-141 acts on desire signals in the brain, not on blood flow.
- Vyleesi® is a small shot taken about 45 minutes before anticipated sexual activity.
- Vyleesi® can briefly raise blood pressure, so it is not for everyone.
What readers want to figure out?
- You want a plain definition of PT-141 without a science lecture.
- You want to know why one thing has three different names.
- You want to understand how PT-141 works in the body.
- You want to know who Vyleesi® is approved to help, and who it is not.
- You want the key safety facts before you consider it.
What PT-141 is, in one sentence?
PT-141 is a small peptide, and its formal drug name is bremelanotide. The FDA-approved medicine made from it is called Vyleesi®. So Vyleesi® is the product a clinician can prescribe.
In plain terms, PT-141 and bremelanotide name the same molecule. Vyleesi® is the brand you will see on a real prescription. This guide leads with Vyleesi® because that is the reviewed, approved form.
PT-141, bremelanotide, and Vyleesi®: one molecule, three names
Three names for one thing can be confusing. PT-141 was the early research code for the molecule. Bremelanotide is its official generic drug name.
Vyleesi® is the brand name of the FDA-approved medicine. It holds bremelanotide as its active ingredient. The FDA cleared it in 2019 after a full review.
You may also see “PT-141” sold online as a research chemical. That version is not the FDA-approved medicine, and it has not passed the same review. The dose, purity, and quality of those products are not assured.
PT-141 and bremelanotide are the same molecule. The FDA-approved medicine made from it is Vyleesi®.
How PT-141 works, in plain terms?
Many people expect a sexual medicine to work on blood flow. PT-141 is different. It acts on signals in the brain, not on blood vessels.
PT-141 is a melanocortin receptor agonist. That means it switches on a group of brain receptors called melanocortin receptors. The one linked to sexual desire is the melanocortin-4 receptor, or MC4R.
By acting on this pathway, PT-141 is thought to raise sexual desire. The exact way it works is not fully known. That honest gap is normal for medicines that act in the brain.
This is why Vyleesi® is taken before intimacy, not every day. It nudges desire signals, rather than fixing a physical block. Desire and blood flow are two different targets.
What Vyleesi® is FDA-approved for?
Vyleesi® has one approved use. It is for premenopausal women with acquired, generalized HSDD. HSDD stands for hypoactive sexual desire disorder.
Those two words matter. Acquired means the low desire is new for you, not lifelong. Generalized means it happens in most settings, not just one.
The low desire must also cause you real distress. It should not be explained by a health problem, a medication, or relationship issues alone. A licensed clinician confirms the diagnosis.
The label sets clear limits too. Vyleesi® is not for postmenopausal women, and it is not for men. It is not meant to boost sexual performance.
How Vyleesi® is taken?
Vyleesi® comes as a small shot you give yourself. The dose is 1.75 mg under the skin. You inject it into your belly or your thigh.
The timing is as-needed, not daily. You use it about 45 minutes before you expect sexual activity. It is made for the moment, not for every day.
There are simple limits on the label. You should not take more than one dose in 24 hours. You should not use more than eight doses in a month.
A prescriber also watches your progress. Vyleesi® may be stopped after 8 weeks if it has not helped. That check keeps you from staying on something that is not working.
Vyleesi® is used as needed, about 45 minutes before intimacy, not as a daily pill.
Safety basics to know
Vyleesi® has one safety point that stands out. It can briefly raise your blood pressure after each dose. It can also slow your heart rate for a short time.
These changes are usually short-lived. They tend to settle within about 12 hours. Still, they are the reason for careful screening.
Because of this, Vyleesi® is not for everyone. It should not be used with uncontrolled high blood pressure. It should not be used with known heart disease.
The most common side effect is nausea, reported by about 40% of women in studies. Flushing and headache are also common. Most side effects are mild or moderate and ease with time.
What the RECONNECT trials found?
The main evidence for Vyleesi® comes from RECONNECT. This was a pair of phase 3 trials, called Study 301 and Study 302. Both compared Vyleesi® to a placebo over 24 weeks.
About 1,247 premenopausal women took part across the two trials. All had acquired, generalized HSDD. They used the 1.75 mg shot as needed.
Women on Vyleesi® saw a real rise in sexual desire. On the desire score, the combined gain over placebo was 0.35 (P<0.001). That result was statistically significant.
Women on Vyleesi® also felt less distress about low desire. On the distress score, the combined result was a drop of 0.33 versus placebo (P<0.001). These numbers apply to the FDA-approved product.
What PT-141 is not for?
It helps to be clear about scope. Vyleesi® is not approved for men. It is not approved for postmenopausal women.
It is also not a general desire booster for anyone. It is not meant for people without HSDD. And it does not increase blood flow, so it works differently from medicines that do.
One more point on names. The FDA-approved form is the prescription medicine Vyleesi®. Products sold only as “PT-141” are not the reviewed, approved medicine.
PT-141 (Vyleesi®) at a glance
Here are the key facts in one view. The table sums up what Vyleesi® is, its approved use, how it is taken, and its main caution.
| Feature | Detail |
|---|---|
| Names | PT-141 (research name), bremelanotide (drug name), Vyleesi® (FDA-approved brand) |
| Drug class | Melanocortin receptor agonist (acts on MC4R in the brain) |
| FDA-approved use | Premenopausal women with acquired, generalized HSDD |
| How it is taken | 1.75 mg shot under the skin, as needed, about 45 minutes before activity |
| Label limits | No more than 1 dose per 24 hours; no more than 8 doses per month |
| Main caution | Brief blood pressure rise; not for uncontrolled hypertension or known heart disease |
| Key evidence | RECONNECT phase 3 trials in about 1,247 premenopausal women |
Where to learn more?
You now know what PT-141 is and what Vyleesi® is approved to do. If you think it may fit, a licensed clinician is the right next step. Vyleesi® is prescription-only, so a clinician must review your health first.
Many people now start that conversation through licensed telehealth. It helps to compare options on how they operate, not on hype. A side-by-side look can make the choice easier.
The Bottom Line
PT-141 is the research name for bremelanotide, the peptide inside the medicine Vyleesi®. Vyleesi® is FDA-approved for premenopausal women with acquired, generalized HSDD. It acts on desire signals in the brain, not on blood flow.
Keep the key facts in mind. Vyleesi® is a small shot used as needed, and it can briefly raise blood pressure. Its evidence comes from the RECONNECT trials in about 1,247 women.
If PT-141 sounds like a fit, the next step is a licensed clinician. Vyleesi® is prescription-only, so your health comes first. A careful comparison can help you decide where to go.
FREQUENTLY ASKED QUESTIONS
PT-141 is the research name for a small peptide called bremelanotide. The FDA-approved medicine made from it is Vyleesi®. It is a melanocortin receptor agonist, which means it acts on desire signals in the brain. The FDA approved Vyleesi® in 2019 for premenopausal women with acquired, generalized HSDD. You may also see the name bremelanotide on medical pages.
They are closely linked. PT-141 and bremelanotide are two names for the same molecule. Vyleesi® is the FDA-approved medicine that contains bremelanotide as its active ingredient. So Vyleesi® is the reviewed, prescription form a clinician can provide. Products sold online only as “PT-141” are not the FDA-approved medicine and have not passed the same safety review.
PT-141 acts on the brain, not on blood flow. It is a melanocortin receptor agonist, so it switches on melanocortin receptors. The one tied to sexual desire is the melanocortin-4 receptor. By acting on this pathway, PT-141 is thought to raise sexual desire. The exact mechanism is not fully understood, which is common for medicines that work in the brain.
Vyleesi® is FDA-approved for premenopausal women with acquired, generalized HSDD. Acquired means the low desire is new, not lifelong. Generalized means it happens in most settings. The low desire must also cause real distress. The label states that Vyleesi® is not for postmenopausal women, not for men, and not for boosting sexual performance. A clinician confirms the diagnosis first.
You give yourself Vyleesi® as a 1.75 mg shot under the skin. You inject it into your belly or thigh, about 45 minutes before anticipated sexual activity. It is used as needed, not daily. The label says not to take more than one dose in 24 hours, or more than eight doses in a month. A prescriber may stop it after 8 weeks if it has not helped.
For the approved medicine Vyleesi®, the main safety point is blood pressure. Vyleesi® can briefly raise blood pressure and slow heart rate after each dose, usually easing within 12 hours. Because of this, it is not for people with uncontrolled high blood pressure or known heart disease. The most common side effects are nausea, flushing, and headache. A clinician checks your heart health first.
RECONNECT was a pair of phase 3 trials, Study 301 and Study 302. About 1,247 premenopausal women with HSDD took part over 24 weeks. Women on Vyleesi® had a significant rise in sexual desire (combined gain 0.35, P<0.001). They also felt less distress about low desire (combined drop 0.33, P<0.001). These results apply to the FDA-approved product.
Keep Reading
Where to get Vyleesi®: compare licensed providers
You know what PT-141 is. Next, see how licensed telehealth providers compare on how they operate, not on hype.
→ Read next: /compare/vyleesi-providers/
SOURCES
1. VYLEESI® (bremelanotide injection) Prescribing Information. US Food and Drug Administration. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
2. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstet Gynecol. 2019;134(5):899-908. https://pmc.ncbi.nlm.nih.gov/articles/PMC6819021/
3. US Food and Drug Administration. Vyleesi® Approval Package (NDA 210557). 2019. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000Approv.pdf
4. DailyMed. VYLEESI (bremelanotide injection) label. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bremelanotide. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK573221/
6. Clayton AH, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health. 2022. https://pubmed.ncbi.nlm.nih.gov/35230162/
Last updated: 2026-07-10 · Editorially reviewed by the Peptides.io team
Comments